Mental illness represents the leading cause of disability burden in Australia. Given an ageing population and the ongoing demands of the modernlifestyle, the incidence of neuropsychiatric disease is on the rise.
Unfortunately, the attrition rate associated with novel drug discovery for central nervous system (CNS) disorders is unacceptably high. This reflects the difficulty in understanding and treating diseases such asschizophrenia, anxiety and depression, which are complex and polygenic in nature.
DDB's studies focus on understanding how modulation of G protein-coupled receptor targets in the CNS can provide new insights into mechanisms underlying neuropsychiatric disease—in particular deficits associated with schizophrenia—and identify novel therapeutic modalities.
Metabolic G protein-coupled receptor group
metabolic and endocrine disorders, neuropsychiatric disease, allosteric modulation, biased agonism, structural biology, chemical biology, integrated pharmacology, receptor trafficking, compartmentalised signaling
G protein-coupled receptor allosteric modulation and drug targeting
neuropsychiatric diseases, metabolic and endocrine disorders, cardiovascular disease, allosteric modulation, drug discovery, chemical biology, schizophrenia, alzheimer’s disease, structural biology, biased agonism
Class C GPCR biology
neuropsychiatric diseases, schizophrenia, alzheimer's disease, allosteric modulation, neuronal culture, cell signalling, chemical biology, structural biology, dimerization, mutagenesis
Stem cell biology laboratory
Parkinson's disease, neuro inflammation, neuro degeneration, neuro psychiatric disease, neuro development, renal disease, alport syndrome, cardiovascular disease
Dopamine receptor pharmacology
neuro psychiatric disease, parkinson’s disease, schizophrenia, allosteric modulation, biased agonism
Servier program in drug discovery - molecular and translational drug discovery
neuro psychiatric disease, inflammation, metabolic and endocrine disorders, drug discovery, orphan G protein-coupled receptors, high-throughout screening, hits-to-leads, translational biology, high content imaging, biased agonism
Muscarinic receptors group
neuro psychiatric disorders, asthma/COPD, endogenous and synthetic allosteric modulators, GPCRs